检索结果-南通市图书馆

Survey of hepatitis b virus infection for liver cancer screening in China:A population-based,cross-sectional study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第12期137卷 1414-1420页

作者： Yongjie Xu Changfa Xia He Li Maomao Cao Fan Yang Qianru Li Mengdi Cao Wanqing Chen Office of Cancer Screening National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Office of National Cancer Regional Medical Centre in Liaoning Province The First Affiliated Hospital of China Medical UniversityShenyangLiaoning 110001China

background:hepatitis b virus(HbV)infection is the primary cause of hepatocellular carcinoma(HCC)in *** target population for HCC screening comprises individuals who test positive for hepatitis b surface antigen(HbsAg).However,current data on the prevalence of HbV infection among individuals who are eligible for HCC screening in China are *** aimed to assess the seroepidemiology of HbV infection among Chinese individuals eligible for HCC screening to provide the latest evidence for appropriate HCC screening strategies in ***:Questionnaires including information of sex,age,ethnicity,marital status,educational level,source of drinking water,as well as smoking and alcohol consumption history and serum samples were collected from females aged 45-64 years and males aged 35-64 years in 21 counties from 4 provinces in eastern and central China between 2015 and ***-linked immunosorbent assay methods were used to detect the serum HbV marker ***:A total of 603,082 individuals were enrolled,and serum samples were collected for analysis from January 1,2015 to December 31,*** prevalence of HbsAg positive in the study population was 5.23%(31,528/603,082).The prevalence of HbsAg positive was greater in males than in females(5.60%[17,660/315,183]vs 4.82%[13,868/287,899],χ^(2)=187.52,Pbited a greater prevalence of HbV infection than younger participants(χ^(2)=41.73,Pbirth cohort analysis revealed an overall downward trend in HbV prevalence for both males and *** born in more recent cohorts exhibited a lower prevalence of HbV infection as compared to those born ***:The current prevalence of HbV infection remains above 5%in populations eligible for HCC screening in *** efforts should be made to increase the accessibility of HCC screening among individuals with HbV infection.

关键词： hepatitis b virus Liver cancer screening China hepatitis b surface antigens Early detection of cancer

Impact of baseline hepatitis b virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2024年第6期16卷 2504-2519页

作者： Di Pan Hao-Nan Liu Zhi-Yuan Yao Xiao-Xiao Chen Yu-Qi Li Jing-Jing Zhu Zheng-Xiang Han Xiao-bing Qin Department of Oncology The Affiliated Hospital of Xuzhou Medical UniversityXuzhou 221000Jiangsu ProvinceChina

bACKGROUND Although the combination of lenvatinib and PD-1 inhibitors has become the standard regimen for the treatment of advanced hepatocellular carcinoma(HCC),real data on the impact of baseline hepatitis b virus(HbV)-DNA levels on the clinical efficacy of this regimen is still *** To evaluate the effectiveness of camrelizumab combined with lenvatinib in patients with HCC at varying levels of *** One hundred and twenty patients with HCC who received camrelizumab and lenvatinib treatment were categorized into two cohorts:HbV-DNA≤2000(n=66)and HbV-DNA>2000(n=54).The main outcomes measured were overall survival(OS)and progression-free survival(PFS),while additional outcomes included the rate of objective response rate(ORR),disease control rate(DCR),and any negative *** proportional hazards regression analysis revealed independent predictors of OS,leading to the creation of a nomogram incorporating these *** The median PFS was 8.32 months for the HbV-DNA≤2000 group,which was similar to the 7.80 months observed for the HbV DNA>2000 group(P=0.88).Likewise,there was no notable variation in the median OS between the two groups,with durations of 13.30 and 14.20 months respectively(P=0.14).The ORR and DCR were compared between the two groups,showing ORR of 19.70%vs 33.33%(P=0.09)and DCR of 72.73%vs 74.07%(P=0.87).The nomogram emphasized the importance of antiviral treatment as the main predictor of patient results,with portal vein tumor thrombus and barcelona Clinic Liver Cancer staging following closely *** The clinical outcomes of patients with HbV-associated HCC treated with camrelizumab in combination with lenvatinib are not significantly affected by HbV viral load.

关键词： hepatitis b virus Hepatocellular carcinoma Camrelizumab Lenvatinib Efficacy

Inhibition of hepatitis b virus via selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第13期30卷 1911-1925页

作者： Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Department of Chinese Medicine State Key Laboratory of Antiviral DrugsThe First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052Henan ProvinceChina The Fifth Medical Center of Chinese PLA General Hospital Beijing 100039China College of Traditional Chinese Medicine Chongqing Medical UniversityChongqing 400010China beijing Key Laboratory of Emerging Infectious Diseases Peking University Ditan Teaching HospitalBeijing 100015China Department of Infectious Diseases State Key Laboratory of Antiviral Drugsthe First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052Henan ProvinceChina

bACKGROUND Liuweiwuling Tablet(LWWL)is a Chinese patent medicine approved for the treatment of chronic inflammation caused by hepatitis b virus(HbV)*** studies have indicated an anti-HbV effect of LWWL,specifically in terms of antigen inhibition,but the underlying mechanism remains *** To investigate the potential mechanism of action of LWWL against *** In vitro experiments utilized three HbV-replicating and three non-HbV-replicating cell *** in vivo experiment involved a hydrodynamic injectionmediated mouse model with HbV *** and metabolomics were used to investigate the underlying mechanisms of action of *** In HepG2.1403F cells,LWWL(0.8 mg/mL)exhibited inhibitory effects on HbV DNA,hepatitis b surface antigen and pregenomic RNA(pgRNA)at rates of 51.36%,24.74%and 50.74%,*** inhibition rates of LWWL(0.8mg/mL)on pgRNA/covalently closed circular DNA in HepG2.1403F,HepG2.2.15 and HepG2.A64 cells were 47.78%,39.51%and 46.74%,*** of transcriptomics and metabolomics showed that the anti-HbV effect of LWWL was primarily linked to pathways related to apoptosis(PI3K-AKT,CASP8-CASP3 and P53 pathways).Apoptosis flow analysis revealed that the apoptosis rate in the LWWL-treated group was significantly higher than in the control group(CG)among HbV-replicating cell lines,including HepG2.2.15(2.92%±1.01%vs 6.68%±2.04%,Pbetween the non-HbV-replicating HepG2 cells(5.04%±0.74%vs 5.51%±1.57%,P>0.05),L02 cells(5.49%±0.80%vs 5.48%±1.01%,P>0.05)and LX2 cells(6.29%±1.54%vs 6.29%±0.88%,P>0.05).TUNEL staining revealed a significantly higher apoptosis rate in the LWWL-treated group than in the CG in the HbVreplicating mouse model,while no noticeable difference in apoptosis rates between the two groups

关键词： hepatitis b virus Chinese patent medicine Antiviral activity Antiviral mechanism Selective apoptosis

Risk of hepatitis b virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第24期30卷 3052-3058页

作者： bansi P Savaliya Ramin Shekouhi Fatima Mubarak Harsheen K Manaise Paola berrios Jimenez Gabrielle Kowkabany Reed A Popp Kyle Popp Emmanuel Gabriel Department of Surgery Medical Academy Named after SI Georgievsky of Vernadsky Crimean Federal UniversitySimferopol 295015CrimeaRussia Division of Plastic and Reconstructive Surgery Department of SurgeryUniversity of FloridaGainesvilleFL 32608United States Department of Surgery Aga Khan UniversityKarachi 74800SindhPakistan Department of Surgery Government Medical College and HospitalChandigarh 160030PunjabIndia Department of Surgery University of Puerto Rico School of MedicineSan Juan 00921Puerto Rico Department of Chemical and biological Engineering University of AlabamaTuscaloosaAL 35487United States Department of Surgery University of Florida College of MedicineGainesvilleFL 32610United States Department of Surgery Florida State UniversityTallahasseeFL 32306United States Department of Surgery Mayo ClinicJacksonvilleFL 32224United States

This editorial commented on an article in the World Journal of Gastroenterology titled“Risks of Reactivation of hepatitis b virus in Oncological Patients Using Tyrosine Kinase-Inhibitors:Case Report and Literature Analysis”by Colapietro et *** this editorial,we focused on providing a more comprehensive exploration of hepatitis b virus reactivation(HbVr)associated with the usage of tyrosine kinase inhibitors(TKIs).It includes insights into the mechanisms underlying HbV reactivation,the temporal relationship between TKIs and HbV reactivation,and preventive *** aim is to understand the need for nucleos(t)ide analogs(NAT)and serial blood tests for early recognition of reactivation and acute liver injury,along with management *** are considered to be an intermediate(1%-10%)of *** guidelines stipulate that patients receiving therapy with high or moderate risks of reactivation or recent cancer diagnosis must have at least tested hepatitis b surface antigen,anti-hepatitis b core antigen(Hbc),and anti-hepatitis b surface ***-Hbc screening in highly endemic areas means people with negative tests should be vaccinated against *** or nucleotide analogs(NAs)like entecavir(ETV),tenofovir disoproxil fumarate(TDF),and tenofovir alafenamide(TAF)form the basis of HbV reactivation prophylaxis and treatment during ***,lamivudine,telbivudine,and adefovir are generally discouraged due to their reduced antiviral efficacy and higher risk of fostering drug-resistant viral ***,these less effective NAs may still be utilized in cases where ETV,TDF,and TAF are not feasible treatment options.

关键词： hepatitis b virus Reactivation Chronic hepatitis b Tyrosine-kinase inhibitor Immunomodulators Immunosuppressant Nucleoside analogue Hemato-oncology

Perioperative remedial antiviral therapy in hepatitis b virus-related hepatocellular carcinoma resection:How to achieve a better outcome

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2024年第5期16卷 1833-1848页

作者： Fan Mu Liang-Shuo Hu Kun Xu Zhen Zhao bai-Cai Yang Yi-Meng Wang Kun Guo Jian-Hua Shi Yi Lv bo Wang Department of Hepatobiliary Surgery First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061Shaanxi ProvinceChina Department of Anaesthesiology First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061Shaanxi ProvinceChina Department of Gynaecology Wenzhou Medical University Affiliated Jiaxing Women and Children HospitalJiaxing 314000Zhejiang ProvinceChina

bACKGROUND Although the benefits of antiviral therapy for hepatitis b virus(HbV)-related hepatocellular carcinoma(HCC)have been proven,researchers have not con-firmed the differences in patient outcomes between patients who received preoperative antiviral therapy for a period of time(at least 24 wk)and patients who received remedial antiviral therapy just before radical resection for HbV-related *** To investigate the efficacy of perioperative remedial antiviral therapy in patients with HbV-related *** A retrospective study of patients who underwent radical resection for HbV-related HCC at the First Affiliated Hospital of Xi’an Jiaotong University from January 2016 to June 2019 was *** the history of antiviral therapy,patients were assigned to remedial antiviral therapy and preoperative antiviral therapy *** Kaplan–Meier analysis revealed significant differences in overall survival(Pbetween the two *** analysis demonstrated that a history of preoperative antiviral treatment was independently related to improved survival(hazard ratio=0.27;95%confidence interval:0.08-0.88;P=0.030).CONCLUSION In patients with HbV-related HCC,it is ideal to receive preoperative long-term antiviral therapy,which helps patients tolerate more extensive hepatectomy;however,remedial antiviral therapy,which reduces preoperative HbV-DNA levels to less than 4 Log10 copies DNA/mL,can also result in improved outcomes.

关键词： Hepatectomy hepatitis b virus Antiviral therapy Hepatocellular carcinoma hepatitis b virus-DNA

Alterations in the gut microbiome after transjugular intrahepatic portosystemic shunt in patients with hepatitis b virus-related portal hypertension

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第31期30卷 3668-3679页

作者： Hong-Wei Zhao Jin-Long Zhang Fu-Quan Liu Zhen-Dong Yue Lei Wang Yu Zhang Cheng-bin Dong Zhen-Chang Wang Department of Radiology Beijing Friendship HospitalCapital Medical UniversityBeijing 100050China Department of Radiology Beijing Tongren HospitalCapital Medical UniversityBeijing 100730China Department of Interventional Radiology Beijing Shijitan HospitalCapital Medical UniversityBeijing 100038China

bACKGROUND Gut microbiota(GM)affects the progression and response to treatment in liver *** GM composition is diverse and associated with different etiologies of liver ***,alterations in GM alterations are observed in patients with portal hypertension(PH)secondary to cirrhosis,with hepatitis b virus(HbV)infection being a major cause of cirrhosis in ***,understanding the role of GM alterations in patients with HbV infection-related PH is *** To evaluate GM alterations in patients with HbV-related PH after transjugular intrahepatic portosystemic shunt(TIPS)*** This was a prospective,observational clinical *** were 30 patients(with a 100%technical success rate)recruited in the present *** with esophagogastric variceal bleeding due to HbV infection-associated PH who underwent TIPS were *** samples were obtained before and one month after TIPS treatment,and GM was analyzed using 16S ribosomal RNA amplicon *** One month after TIPS placement,8 patients developed hepatic encephalopathy(HE)and were assigned to the HE group;the other 22 patients were assigned to the non-HE *** was no substantial disparity in the abundance of GM at the phylum level between the two groups,regardless of TIPS treatment(all,P>0.05).However,following TIPS placement,the following results were observed:(1)The abundance of Haemophilus and Eggerthella increased,whereas that of Anaerostipes,Dialister,butyricicoccus,and Oscillospira declined in the HE group;(2)The richness of Eggerthella,Streptococcus,and bilophila increased,whereas that of Roseburia and Ruminococcus decreased in the non-HE group;and(3)Members from the pathogenic genus Morganella appeared in the HE group but not in the non-HE *** Intestinal microbiota-related synergism may predict the risk of HE following TIPS placement in patients with HbVrelated *** microbiome therapies may be useful for preventing and trea

关键词： Transjugular intrahepatic portosystemic shunt Hepatic encephalopathy Gut microbiota hepatitis b virus Portal hypertension

Association of preoperative antiviral treatment with incidences of post-hepatectomy liver failure in hepatitis b virus-related hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Surgery 2024年第7期16卷 2106-2118页

作者： Xiao Wang Zhao-Yi Lin You Zhou Qin Zhong Zong-Ren Li Xi-Xiang Lin Ming-Gen Hu Kun-Lun He Medical big Data Research Center Chinese PLA General HospitalBeijing 100853China Medical School of Chinese PLA Chinese PLA General HospitalBeijing 100853China Department of Hepatobiliary Surgery Chinese PLA 970th HospitalYantai 264001Shandong ProvinceChina Faculty of Hepato-Pancreato-biliary Surgery The First Medical Center of Chinese PLA General HospitalBeijing 100853China School of Medicine Nankai UniversityTianjin 300071China

bACKGROUND Post-hepatectomy liver failure(PHLF)is a common consequence of radical partial hepatectomy in hepatocellular carcinoma(HCC).AIMS To investigate the relationship between preoperative antiviral therapy and PHLF,as well as assess the potential efficacy of hepatitis b virus(HbV)DNA level in predicting *** A retrospective study was performed involving 1301 HCC patients with HbV who underwent radical *** operating characteristic(ROC)analysis was used to assess the capacity of HbV DNA to predict PHLF and establish the optimal cutoff value for subsequent *** regression analyses were performed to assess the independent risk factors of *** increase in the area under the ROC curve,categorical net reclassification improvement(NRI),and integrated discrimination improvement(IDI)were used to quantify the efficacy of HbV DNA level for predicting *** PbV DNA level with an optimal cutoff value of 269 IU/mL(Pby adding the variable of HbV DNA level had an improvement in area under the curve,categorical NRI,and IDI,particularly for the fibrosis-4 model,with values of 0.729(95%CI:0.705-0.754),1.382(95%CI:1.341-1.423),and 0.112(95%CI:0.110-0.114),*** the above findings were statistically *** In summary,preoperative antiviral treatment can reduce the incidence of PHLF,whereas an increased preoperative HbV DNA level has a correlative relationship with an increased susceptibility to PHLF.

关键词： Hepatocellular carcinoma hepatitis b virus Preoperative antiviral treatment Liver resection Post-hepatectomy liver failure

Global status and trends in hepatitis b virus DNA mutation research from 2003 to 2022:A comprehensive bibliometric view

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Portal Hypertension & Cirrhosis 2024年第1期3卷 14-21页

作者： Ming Li Xiaoming Xu Yong Liu Minxin Mao Yu Geng Shengxia Yin Xin Tong Chao Wu Jie Li Department of Infectious Diseases Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineNanjingJiangsuChina Department of Infectious Diseases Nanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjingJiangsuChina Department of Laboratory Medicine Nanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjingJiangsuChina Institute of viruses and Infectious Diseases Nanjing UniversityNanjingJiangsuChina

Aims:hepatitis b virus(HbV)is an enveloped DNA virus belonging to the Hepadnaviridae *** is a significant contributor to the prevalence of chronic liver disease on a global *** in HbV DNA can affect the diagnosis,treatment,and prognosis of patients with chronic hepatitis *** numerous studies on HbV DNA mutations have been conducted,few bibliometric studies have been performed to *** study aimed to analyze changes in scientific output to gain a better understanding of the current research status and identify potential new research directions in the field of HbV DNA ***:Relevant studies published between 2003 and 2022 were retrieved from the Web of Science Core Collection *** version 6.1.R6 was used to construct network maps to evaluate collaborations among countries,institutions,authors,journals,and ***:In total,1508 publications over the past 20 years were obtained,mainly from China,the United States,and *** major research institutions in China included the University of Hong Kong,Fudan University,and Peking *** Ching Lung was the most productive author,whereas Anna Suk-Fong Lok was the most frequently co-cited *** keyword“HbsAg”was the strongest burst keyword in recent years,indicating possible future study ***:This bibliometric analysis intuitively revealed the overall research status of HbV DNA mutations,providing valuable information for researchers,funding agencies,and policymakers to explore the current research status,research hotspots,and new directions for future research.

关键词： bibliometrics DNA hepatitis b virus mutation

Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis b virus patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2024年第1期16卷 109-111页

作者： Yu-Tong Sun Qian-Qian Chen Department of Gastroenterology The First Medical Center of Chinese PLA General HospitalBeijing 100193China

This letter comments on the article which reported that tenofovir alafenamide may increase blood lipid levels compared with entecavir in patients with chronic hepatitis b published on World J Hepatol 2023 August *** review the related research content,topic selection,methodology,conclusions,strengths and weaknesses of this *** evaluate it in relation to other published relevant articles.

关键词： Tenofovir alafenamide Entecavir Serum lipid levels hepatitis b virus